Renal cell carcinoma
Also known as: RCC, renal carcinoma, renal cell cancer, renal adenocarcinoma
Renal cell carcinoma (RCC) is a primary malignancy of the renal tubular epithelium, most frequently presenting as the clear cell subtype. Clinical management necessitates specialist urological and oncological assessment for staging, surveillance, surgical intervention, or systemic therapy. Traditional Chinese Medicine (TCM) may be utilised as an adjunct for supportive care but must not delay or replace conventional oncological protocols. Current evidence, including mechanistic reviews and laboratory models, does not demonstrate efficacy for acupuncture or herbal medicine regarding tumour control, survival rates, or RCC-specific symptomatology. TCM patterns reflect symptomatic presentations rather than the underlying biology or staging of the malignancy. All herbal interventions require review by the oncology and pharmacy teams, particularly in the context of impaired renal function or concurrent systemic anticancer therapies.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Prioritise all oncology, urology, imaging, and laboratory consultations, including post-surgical surveillance protocols.
- •Adhere to nutritional and fluid intake parameters established by the renal or oncology teams; avoid unverified 'detoxification' regimens and unreviewed supplements.
- •Maintain gentle physical activity and pacing as tolerated within the clinical constraints of the treating team, particularly post-operatively or where osseous metastases are suspected.
- •Maintain consistent sleep hygiene and access professional psychological, social, or smoking-cessation support services as indicated.
Cautions & Contraindications
- •Do not replace or delay surgery, systemic therapy or surveillance with Chinese medicine. The supplied breast-cancer case illustrates the danger of abandoning standard treatment but does not quantify that risk in RCC.[]
- •Do not present MYC modulation or PD-L1 findings as proof that a formula enhances immunotherapy, shrinks RCC or improves survival. The supplied mechanistic review and laboratory/mouse study do not establish these clinical benefits or safe combinations.[,]
- •Defer needling pending medical clearance with significant thrombocytopenia, neutropenia, active bleeding or infection; avoid tumour sites, healing surgical fields and deep renal-region needling. These are general clinical precautions, not recommendations tested in the supplied RCC reports.[]
- •Do not commence herbs during RCC drug therapy, renal deterioration or unexplained liver-test abnormalities without oncology-pharmacy review. Mechanistic discussion of natural compounds does not establish clinical safety or interaction compatibility.[]
When to reassess or seek care again
If medically cleared, review supportive care after 2–4 weeks using baseline and follow-up 0–10 fatigue, nausea, pain and sleep scores, weekly weight and functional activity. Stop or modify adjunctive treatment if symptoms worsen or no meaningful benefit occurs. Refer promptly for progressive pain, weight loss, haematuria or new symptoms; use emergency pathways for red flags. Cancer response remains assessed by the oncology team's imaging and clinical monitoring, not tongue or pulse changes.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Biochemical pharmacology · 2026
- Medical oncology (Northwood, London, England) · 2026
- Journal of clinical ultrasound : JCU · 2026
- Frontiers in oncology · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
